These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9169641)

  • 1. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect.
    van Besien KW; de Lima M; Giralt SA; Moore DF; Khouri IF; Rondón G; Mehra R; Andersson BS; Dyer C; Cleary K; Przepiorka D; Gajewski JL; Champlin RE
    Bone Marrow Transplant; 1997 May; 19(10):977-82. PubMed ID: 9169641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
    Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
    Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
    Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ; Daugherty CK; Larson RA
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
    van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor leukocyte transfusions and discontinuation of immunosuppressants to achieve an initial remission after allogeneic bone marrow transplantation in a patient with primary refractory acute leukemia.
    Azuno Y; Kaneko T; Nishimura M; Okuya S; Nakai K; Nomiyama J; Mori K; Okafuji K; Okubo M; Matsutani A; Kamei S; Zaitsu Y; Takeuchi Y; Oka Y; Kaku K
    Bone Marrow Transplant; 1996 Jul; 18(1):257-9. PubMed ID: 8832032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
    Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.
    Teuffel O; Schrauder A; Sykora KW; Zimmermann M; Reiter A; Welte K; Schrappe M
    Bone Marrow Transplant; 2005 Jul; 36(2):145-50. PubMed ID: 15908976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
    Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrelated bone marrow transplantation for high-risk anaplastic large cell lymphoma in pediatric patients: a single center case series.
    Cesaro S; Pillon M; Visintin G; Putti MC; Gazzola MV; D'Amore E; Scarzello G; Zanesco L; Messina C; Rosolen A
    Eur J Haematol; 2005 Jul; 75(1):22-6. PubMed ID: 15946306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of allogeneic transplantation in low-grade lymphoma and chronic lymphocytic leukemia.
    Thomson KJ; Mackinnon S
    Curr Opin Hematol; 2006 Jul; 13(4):273-9. PubMed ID: 16755225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study.
    Choi SJ; Lee JH; Lee JH; Kim S; Lee YS; Seol M; Ryu SG; Lee JS; Kim WK; Jang S; Park CJ; Chi HS; Lee KH
    Bone Marrow Transplant; 2005 Jul; 36(2):163-9. PubMed ID: 15937507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma.
    Seropian S; Bahceci E; Cooper DL
    Bone Marrow Transplant; 2003 Oct; 32(8):763-9. PubMed ID: 14520419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.
    Juckett M; Rowlings P; Hessner M; Keever-Taylor C; Burns W; Camitta B; Casper J; Drobyski WR; Hanson G; Horowitz M; Lawton C; Margolis J; Peitryga D; Vesole D
    Bone Marrow Transplant; 1998 May; 21(9):893-9. PubMed ID: 9613781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.